Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement
Subtitle: an in vitro pilot study
Contributors: Ahrens, Ingo 1972- Verfasser; Mauler, Maximilian Verfasser; Bode, Christoph Verfasser; Moser, Martin 1968- Verfasser; Universitäts-Herzzentrum Freiburg - Bad Krozingen; Albert-Ludwigs-Universität Freiburg Medizinische Fakultät; Albert-Ludwigs-Universität Freiburg
Publisher: Universität
Published: 2012
Place of publication: Freiburg
Language: eng
Subjects: Serotoninantagonist; Stent; Koronare Herzkrankheit; Serotoninrezeptor; Biopharmazie; Pharmakodynamik; Pharmakokinetik
Description: Abstract: Increased residual platelet reactivity remains a burden for coronary artery disease (CAD) patients who received a coronary stent and do not respond sufficiently to treatment with acetylsalicylic acid and clopidogrel. We hypothesized that serotonin antagonism reduces high on-treatment platelet reactivity. Whole blood impedance aggregometry was performed with arachidonic acid (AA, 0.5 mM) and adenosine diphosphate (ADP, 6.5 µM) in addition to different concentrations of serotonin (1–100 µM) in whole blood from 42 CAD patients after coronary stent placement and 10 healthy subjects. Serotonin increased aggregation dose-dependently in CAD patients who responded to clopidogrel treatment: After activation with ADP, aggregation increased from 33.7±1.3% to 40.9±2.0% in the presence of 50 µM serotonin (p<0.05) and to 48.2±2.0% with 100 µM serotonin (p<0.001). The platelet serotonin receptor antagonist ketanserin decreased ADP-induced aggregation significantly in clopidogrel low-responders (from 59.9±3.1% to 37.4±3.5, p<0.01), but not in clopidogrel responders. These results were confirmed with light transmission aggregometry in platelet-rich plasma in a subset of patients. Serotonin hence increased residual platelet reactivity in patients who respond to clopidogrel after coronary stent placement. In clopidogrel low-responders, serotonin receptor antagonism improved platelet inhibition, almost reaching responder levels. This may justify further investigation of triple antiplatelet therapy with anti-serotonergic agents
Notes: PLoS ONE. 7, 2 (2012), e32656, DOI 10.1371/journal.pone.0032656, issn: 1932-6203

IN COPYRIGHT http://rightsstatements.org/page/InC/1.0 rs

Archivierung/Langzeitarchivierung gewährleistet